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ABSTRACT: Objective: In the present study, sleep quality and associated factors have 
been evaluated in HIV-positive individuals. Methods: 150 HIV-positive and 50 non-HIV-
positive people were included. Pittsburgh Sleep Quality Index, Hospital Anxiety and 
Depression Scale, somatization subscale of Symptom Checklist-90 were used for evaluation 
of sleep quality, anxiety, depression and physiological factors respectively. Results: 
Statistically significant differences were found regarding sleep quality (p < 0.001) between 
the HIV-positive and control group. There was significant direct correlation between sleep 
quality and each of somatization subscale of Symptom Checklist-90, depression and anxiety 
scores in HIV-positive individuals. Conclusion: Depression, anxiety and physical morbidity 
were detected as main factors that affect sleep quality in the HIV-positive individuals.
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Sleep disturbance is common in HIV-positive individuals [1–3]. Significant increase of slow wave 
sleep [4], alternations in sleep architecture [5], longer sleep onset latency, earlier morning awaken-
ing, more frequent awakenings during the night and reduced sleep efficiency have been reported 
frequently in these patients [6–9]. The prevalence of sleep disturbance in HIV-positive population 
was reported as high as 100% [1,10], while in general population the prevalence rate was 10–40%  [3]. 
In addition, insomnia causes chronic fatigue, antiretroviral nonadherence and also affects the qual-
ity of life, physical and social functioning of HIV-positive patients [3]. Different factors including 
environmental, demographic, physiological and psychological factors affect sleep quality in this 
population [11–13]. There is a strong correlation between sleep disturbance and depression and anxi-
ety. Depressed individuals usually are exposed to high level of sleep disturbance [6,14]. In addition, 
anxiety disorders can lead to delay sleep onset and reduced total sleep time [14]. During progres-
sion of HIV infection, sleep quality is affected by physical symptoms of HIV disease including 
fever, diarrhea, pain, cough, abdominal cramping, incontinence, itching, burning, night sweats 
and dyspnea [6]. Also many antiretroviral drugs especially efavirenz can lead to sleep disturbance, 
depression, anxiety and exacerbation of the physical symptom [3,15–17]. Other medications including 
benzodiazepines, barbiturates, narcotics and drugs used for treatment of opportunistic infections 
also can cause sleep disturbance [2]. In the present study, sleep quality and associated factors includ-
ing demographic characteristics, anxiety–depression and physical morbidity have been evaluated 
in HIV-positive individuals.
Methods
This cross-sectional study was conducted in HIV clinic of Imam Khomeini Hospital, affiliated 
to Tehran University of Medical Sciences, Tehran, Iran from March 2013 to April 2014. The 
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hospital’s ethical committee approved the study 
protocol and all participants signed the study 
informed contest form. 200 individuals aged 
between 21 and 62 years, including 150 HIV-
positive patients and 50 non-HIV-positive indi-
viduals (as control group), were included. HIV 
infection of the patients confirmed based on 
the ELISA and western-blot tests. Demographic 
data including sex, age, weight, routes of HIV 
transmission, education level, job, marital sta-
tus, opportunistic infections and concomitant 
diseases of the subjects were collected. As it was 
reported that efavirenz can cause severe sleep 
disturbance [9], HIV-positive patients divided 
into three groups; received antiretroviral ther-
apy (ART) including efavirenz, received ART 
without efavirenz and did not receive ART. Also 
for further analysis these patients were catego-
rized into two groups; good and poor sleep qual-
ity. The validated Persian version of question-
naires including Pittsburgh Sleep Quality Index 
(PSQI) [18], Hospital Anxiety and Depression 
Scale (HADS) [19] and somatization subscale 
of Symptom Checklist-90 (SCL-90) [20,21] were 
used for evaluation of sleep quality, anxiety 
symptoms, depression symptoms and physiolog-
ical factors of the included individuals respec-
tively. PSQI is a self-report instrument based 
on the sleep quality measuring, in the range of 
0–21. A greater amount of this value demon-
strates a higher level of sleep disturbance. The 
patients with PSQI score above five were con-
sidered as poor sleepers. The sleep quality was 
examined by considering seven domains con-
taining subjective sleep quality, sleep latency, 
sleep duration, habitual sleep efficiency, sleep 
disturbance, use of sleeping medication and day 
time dysfunction during last month [9]. HADS 
is a well-known self-reported instrument and 
consists of 14 items for measuring the cognitive 
symptomatology of both anxiety (seven items) 
and depression (seven items). Each item is rated 
from 0 to 3. It has four cutoff points of severity 
(scores: 0–7 normal; 8–10 mild; 11–14 moder-
ate and 15–21 severe). It should be mentioned 
that HADS is a psychological screening tool, 
not a diagnostic measurement [19,22]. SCL-90 
is another self-reported questionnaire that was 
used in this study to evaluate physiological fac-
tors. This questionnaire consists of 12 items 
reported distress in variety of system such as 
gastrointestinal, cardiovascular and autonomic 
system and each item scores between 0 (none) 
to 4 (extreme) [23].
Statistical Package of Social Science ver-
sion 16 was used for data analysis. Due to non-
normal distribution of the data (evaluated by 
Kolmograph Smirnov test), the nonparametric 
Mann–Whitney U-test and Kruskal–Wallis one-
way analysis of variance were used to compare 
quantitative data between two and more than 
two groups, respectively. We used Chi-square 
test for analysis of qualitative data. The statisti-
cal significance level for all tests was considered 
as p < 0.05. Correlations between quantitative 
variables were assessed based on Spearman 
rank test. As multiple comparisons for this test, 
p-value less than 0.01 was considered statistically 
significant.
Results
Demographic data of included individuals were 
summarized in Table 1. HIV-positive group con-
sisted of 100 males (67%) and 50 (33%) females 
with mean ± SD age of 35.90 ± 7.75 years old. 
Control group consisted of 30 males (60%) 
and 20 females (40%) with mean ± SD age of 
34.76 ± 7.36 years old. Sexual contact (51%) fol-
lowed by injection drug use (43%) were the most 
common routes of HIV transmission in this cohort. 
Hepatitis C virus infection was the most com-
mon concomitant infection in the HIV-positive 
individuals and was detected in 53 (35.33%) of 
them. Sleep disturbances were detected in 88 
(55.30%) and 14 (28%) of HIV and non-HIV-
positive patients, respectively. Statistically sig-
nificant differences were found regarding PSQI 
(median ± IQR: 6.00 ± 7 vs 4.00 ± 4; p < 0.001), 
somatization subscale of SCL-90 (median ± IQR: 
11.00 ± 14 vs 26.00 ± 5; p < 0.001), depression 
(median ± IQR: 7.00 ± 7 vs 4.00 ± 4; p < 0.001) 
and anxiety (median ± IQR: 8.50 ± 8 vs 4.50 ± 5; 
p < 0.001) scores between the HIV-positive and 
control group. Also seven components of PSQI 
questionnaire (subjective sleep quality, sleep 
latency, sleep duration, habitual sleep efficiency, 
sleep disturbances, use of sleeping medications 
and daytime dysfunction) have been compared 
between the HIV-positive and control group. 
Only five components (sleep latency, sleep dura-
tion, habitual sleep efficiency, sleep disturbances 
and daytime dysfunction) showed statistically sig-
nificant differences between the groups (Table 2).
There was not any significant difference in sleep 
quality (p = 0.30), anxiety (p = 0.13) and depres-
sion (p = 0.30) scores among HIV-positive patients 
who received ART including efavirenz, ART with-
out efavirenz and no ART. However, there was 
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weak but significant direct correlation between the 
PSQI and each of somatization subscale of SCL-
90 (r = 0.508; p < 0.001), depression (r = 0.457; 
p < 0.001) and anxiety (r = 0.391; p < 0.001) 
scores in HIV-positive individuals. There was no 
statistically significant correlation between PSQI 
scores and age, weight, time from HIV-infection 
diagnosis (median ± IQR: 27 ± 45 months), dura-
tion of ART (median ± IQR: 24 ± 38 months) 
and CD4 count (r = 0.04; p = 0.63). Effects of 
different demographic factors including employ-
ment status, education level, marital condition, 
smoking behavior, alcohol addiction and living 
status on the patient’s sleep quality also have been 
investigated (Table 3). There was not any significant 
difference in the sleep quality between the patients 
receiving efavairenz or not (p = 0.56). Among all 
evaluated factors, only the patient’s employment 
(p = 0.005) and education (p = 0.04) status had 
significant effect on the sleep quality. Depression 
score of the HIV-positive patients was categorized 
as normal (n = 76; 50.67%) or mild (n = 29; 
19.33%), moderate (n = 29; 19.33%) and severe 
(n = 16; 10.66%) depression. Severity of anxiety 
of the HIV-positive patients also was divided into 
normal (n = 67; 44.67%), mild (n = 27; 18%), 
moderate (n = 31; 20.67%) and severe (n = 25; 
16.67%).
Discussion
Sleep disturbance was detected in 55.3 and 28% 
of Iranian HIV-infected and healthy participants 
respectively. In previous study, incidence of sleep 
disturbance was reported in 47.5% of Iranian HIV-
positive individuals [24]. In other countries, sleep 
disturbance was reported in 63–100% of these 
patients [1,9,10]. Significant difference in the sleep 
quality was detected between the HIV-infected 
Table 1. Demographic data of the HIV and non-HIV-positive individuals.
Characteristic HIV-infected patients 
(n = 150); n (%)
Non-HIV-positive 
individuals (n = 50); n (%)
p-value†
Age (mean ± SD), years 35.90 ± 7.75 34.76 ± 7.36
Sex: 
– Male 
– Female
 
100 (67) 
50 (33)
 
30 (60) 
20 (30)
 
0.39 
Employment status: 
– Employed 
– Unemployed
 
86 (57) 
64 (43)
 
42 (84) 
8 (16)
 
0.001 
Education level: 
– Primary 
– Intermediate 
– High school 
– Advanced
 
16 (11) 
62 (41) 
52 (35) 
20 (13)
 
0 (0) 
1 (2) 
19 (38) 
30 (60)
 
p < 0.001   
Marital status: 
– Single 
– Married 
– Divorced
 
61 (41) 
75 (50) 
14 (9)
 
9 (18) 
40 (80) 
1 (2)
 
0.001  
HIV transmission routes: 
– Sexual contact 
– Intravenous drug injection 
– Blood products 
– Unknown
 
76 (51) 
64 (43) 
8 (5) 
2 (1)
 
0 
0 
0 
0
    
Concomitant diseases: 
– Hepatitis B 
– Hepatitis C 
– Metabolic diseases 
– Psychiatric diseases 
– Gastrointestinal disorders 
– Renal disorders 
– Skin problems 
– Respiratory disorders 
– Others
 
1 (0.67) 
53 (35.33) 
6 (4) 
9 (6) 
1 (0.67) 
2 (1.33) 
1 (0.667) 
2 (1.33) 
9 (6)
 
0 
0 
  
0 
0 
0 
0 
0 
0
         
†Chi-square test.  
SD: Standard deviation.
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patients and control group. This difference also 
has been reported in the previous studies [3,9]. 
In a cross-sectional study by Wibbeler et al., 
sleep quality has been compared between HIV-
positive patients who did not receive efavirenz and 
non-HIV-positive individuals. They used PSQI 
and reported significant differences in all seven 
domains of PSQI between the groups [9]. However, 
we did not find significant differences in the sub-
jective sleep quality and use of sleeping medica-
tion domains between the groups. Furthermore in 
Gallego et al. study, significant difference in the 
sleep latency was detected between HIV-positive 
patients receiving efavirenz and non-HIV-positive 
individuals. Also, HIV-positive patients with 
insomnia who received efavirenz had significant 
reduction in sleep efficiency and increase in rapid 
eye movement episodes and related vivid dreams. 
These patients regardless of normal or poor sleep 
quality had reduced deep-sleep duration [15]. In our 
study, ART regimen containing efavirenz did not 
significantly affect the HIV-positive patient’s 
Table 2. Comparison of seven components of Pittsburgh Sleep Quality Index.
Domain HIV-positive 
patients 
(n = 150); n (%)
Non-HIV-positive 
individuals (n = 50); 
n (%)
p-value†
Subjective sleep quality:
– Very good 33 (22.00) 12 (24.00) 0.09
– Fairly good 74 (49.33) 30 (60.00)  
– Fairly bad 27 (18.00) 8 (16.00)  
– Very bad 16 (10.67) 0  
Sleep latency:
– <15 min, not during the past month 16 (10.67) 18 (36.00) < 0.001
– 16–30 min, less than once per week 41 (27.33) 28 (56.00)  
– 31–60 min, once or twice per week 40 (26.67) 4 (8.00)  
– >60 min, three- or more times per week 53 (35.33) 0  
Sleep duration:
– >7 h 91 (60.67) 30 (60.00) 0.03
– 6–7 h 35 (23.33) 19 (38.00)  
– 5–6 h 13 (8.67) 1 (2.00)  
– <5 h 11 (7.33) 0  
Habitual sleep efficiency:
– >85% 93 (62.00) 46 (92.00) 0.003
– 75–85% 27 (18.00) 3 (6.00)  
– 65–74% 23 (15.33) 1 (2.00)  
– <65% 6 (4.00) 0  
Sleep disturbances:
– None 14 (9.33) 8 (16.00) 0.04
– 1–9 68 (45.33) 29 (58.00)  
– 10–18 55 (36.67) 13 (26.00)  
– 19–27 13 (8.67) 0  
Use of sleeping medication:
– Not during the past month 115 (76.67) 44 (88.0) 0.06
– Less than once per week 15 (10.00) 6 (12.0)  
– Once or twice per week 5 (3.33) 0  
– Three or more times per week 15 (10.00) 0  
Daytime dysfunction:
– Never, no problem at all 53 (35.33) 32 (64.00) <0.001
– One- or two-times per week, only a very slight                         
p problem
44 (29.33) 14 (28.00)  
– One- to two-times per week, somewhat of a problem 34 (22.67) 4 (8.00)  
– Three- or more times per week, a very big problem 19 (12.67) 0  
†Chi-square test.
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sleep quality, anxiety and depression scores. The 
neuropsychiatric adverse effects of efavirenz most 
commonly occur during the first month of ART 
and thereafter may be detectable in only 13% of 
patients [25,26]. The majority of our patricians were 
not in the first month of ART.
HIV infection itself can cause a variety of 
psychiatric and neurocognitive complications 
Table 3. Associated factors of sleep quality in the HIV-positive patients.
Factor Sleep quality; n (%) p-value†
  Good sleep Poor sleep  
Gender:
– Male 44 (29.33) 56 (37.33) 0.35
– Female 18 (12.00) 32 (21.33)  
Employment status:
– Employed 44 (29.33) 42 (28.00) 0.005
– Unemployed 18 (12.00) 46 (39.13)  
Education level:
– Primary 2 (1.33) 14 (9.00) 0.04
– Intermediate 32 (21.33) 30 (20.00)  
– High school 20 (13.00) 32 (21.33)  
– Advanced 8 (5.00) 12 (8.00)  
Marital status:
– Single 23 (15.33) 38 (25.33) 0.75
– Married 33 (22.00) 42 (28.00)  
– Divorced 6 (4.00) 8 (5.00)  
HIV transmission routes:
– Sex 28 (18.67) 48 (32.00) 0.27
– Intravenous drug injection 28 (18.67) 36 (24.00)  
– Blood 4 (2.67) 4 (2.67)  
– Unknown 2 (1.33) 0  
Smoking:
– Yes 36 (24.00) 51 (34.00) 0.99
– No 26 (17.33) 37 (24.67)  
Alcohol use:
– Yes 7 (4.67) 12 (8.00) 0.67
– No 55 (36.67) 76 (51.00)  
Substance abuse:
– Yes 31 (20.67) 49 (32.67) 0.49
– No 31 (20.67) 39 (26.00)  
Family support:
– Yes 54 (36.00) 76 (51.00 0.89
– No 8 (5.00) 12 (8.00)  
Living in own house:
– Yes 56 (37.33) 81 (54.00) 0.71
– No 6 (4.00) 7 (4.67)  
Imprison history:
– Yes 27 (18.00) 40 (26.67) 0.82
– No 35 (23.33) 48 (32.00)  
Receiving efavirenz:
– Yes 34 (22.67) 44 (29.33) 0.56
– No 28 (18.67) 44 (29.33)  
Hepatitis C infection:
– Yes 24 (16.00) 29 (19.33) 0.47
– No 38 (25.33) 59 (39.33)  
†Chi-square test.
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including dizziness, headache, nightmares, 
abnormal dreams, mild cognitive difficulty, 
sleep disturbance (somnolence and insomnia), 
impaired concentration, depression, halluci-
nation, delusion, paranoia, anxiety, agitation, 
aggressive behavior, mania, emotional lability, 
catatonia, melancholia, psychosis and fatigue 
that may overlap significantly with psychiatric 
adverse effects of ART. The most common neu-
rologic manifestations in HIV/AIDS individu-
als are minor cognitive and motor disorder and 
HIV-associated dementia. The most common 
psychiatric manifestations are depressive spec-
trum disorders. HIV-associated neurocognitive 
disorders (HAND) are neurological disorders 
associated with HIV infection and AIDS. 
HAND may include neurological disorders of 
various severity such as AIDS dementia com-
plex also known as HIV dementia and HIV-
associated dementia, HIV encephalopathy and 
mild neurocognitive disorder [25–28].
Sleep disturbance may be an early symptom of 
CNS involvement in HIV-positive individuals. 
Fatigue and insomnia in asymptomatic HIV-
infected patients may be related to psychologi-
cal disturbances including major depression. 
Periodic assessment of HIV-infected patients 
who complain of fatigue or insomnia is recom-
mended [28,29].
We have not specif ically evaluated the 
included patients regarding to the HANDS 
based on the diagnostic criteria. Correlation 
between HANDS and sleep disturbances in 
HIV-positive Iranian population should be 
considered in the future studies.
Reduction of viral load and regulation of 
HIV-induced immune and endocrine activa-
tion following ART may lead to improve sleep 
quality in these patients. Adjusting admin-
istrating times of antiretroviral medications 
can also decrease their sleep disturbances [2]. 
We did not detect any significant correlation 
between the patient’s CD4 cell count and 
sleep quality. Some studies suggested inverse 
correlation between immune system activity 
and sleep quality in HIV-positive patients 
[29] but others did not show this relationship. 
However, boosting immune system following 
antiretroviral therapy may improve HANDS 
and consequently improve sleep quality in 
this population [11]. Further future studies are 
needed to clarify correlation between immune 
system function, HANDS and sleep quality in 
HIV-positive individuals.
Significant direct correlations were observed 
between PSQI and each of anxiety, depression 
and physical morbidity among Iranian HIV-
infected patients. These findings also have 
been reported in the previous studies [3,6,9]. In 
Wibbeler et al. study, depression is defined as the 
most important factor that affects sleep quality 
in HIV-positive individuals [9]. Pain as a physi-
ologic factor and depression and anxiety as two 
psychological factors showed strong correlation 
with sleep quality of HIV-positive individuals 
in Robbins et al. study [6]. HIV-positive patients 
are vulnerable to depression and anxiety as psy-
chological disorders. Due to depression, HIV-
infected patients experience high levels of anxi-
ety and more sleep difficulties including more 
problems in falling asleep, decreased slow-wave 
and more nonrapid-eye-movement sleep. Vice 
versa, anxiety and sleep disturbances may pro-
mote or affect depression severity [3,6].
Among the demographic factors, only 
employment status and education level had 
significant effect on sleep quality in the HIV-
positive individuals. In Saberi et al. cross-sec-
tional study, depression, unemployment, use of 
illicit substances, history of incarceration were 
associated with poor sleep quality in HIV-
positive individuals [13]. Also emotional stress 
and pain can affect sleep quality in HIV-positive 
patients [12]. Substance dependency is a main 
cause of insomnia in HIV-positive people [2]. 
Significant correlations between sleep quality of 
HIV-positive individuals and each of the times 
of living with HIV infection, substance abuse 
including cigarettes, receiving ART, anxiety, 
depressive symptoms and sleeping alone have 
been reported by Nokes et al. They did not find 
any relation between the patient’s age, employ-
ment status and route of HIV transmission [11]. 
However, we did not detect any correlation 
between sleep quality and social support, sub-
stance abuse and imprisonment in the included 
patients.
Sleep disturbances have negative effects on 
mood, cognition, physical and social functioning, 
quality of life and life expectancy. Recognition of 
these conditions and applying appropriate inter-
ventions to improve them are essential [2]. In the 
future studies, different nonpharmacological 
and pharmacological inter ventions to improve 
neuropsychiatric complications in HIV-positive 
individuals may be compared.
The main limitation of present study is the rel-
ative small sample size in both patient and control 
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groups which should be considered in future stud-
ies. We also did not have access to the patient’s 
laboratory data including viral load. Evaluation 
of correlation between these parameters and sleep 
quality may show interesting results.
Conclusion
Sleep disturbance was signif icantly more 
common in Iranian HIV-positive individu-
als compared with non-HIV-positive people. 
Depression, anxiety and physical morbidity were 
detected as main factors that affect sleep quality 
in the HIV-positive individuals.
Future perspective
Evaluation of correlation between sleep qual-
ity and each of the following items may show 
interesting results; viral load, CD4 cells count, 
duration and types of ART regimens, adher-
ence to ART, concomitant diseases and oppor-
tunistic infections, and neurocognitive prob-
lems. Appropriate approach and managing of 
predisposing factors of sleep disturbance can 
improve quality of life and life expectancy in 
these patients. As neurocognitive problems are 
common in HIV/AIDS patients that can affect 
sleep quality, defining appropriate and practical 
tools for assessment of these problems should be 
considered in the future studies.
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EXECUTiVE SUMMARY
Introduction
 ●  The prevalence of sleep disturbance in HIV-positive population was reported as high as 100%, while in general 
population the prevalence rate was 10–40%.
Methods
 ●  Sleep quality and associated factors have been evaluated in 200 individuals aged between 21 and 62 years, including 
150 HIV-positive patients and 50 non-HIV-positive individuals (as a control group).
Results
 ●  Sleep disturbances were detected in 88 (55.3%) and 14 (28%) of HIV and non-HIV-positive patients respectively. 
Statistically significant differences were found regarding sleep quality, somatization subscale of somatization 
subscale of Symptom Checklist-90, depression and anxiety scores between the HIV-positive and control group.
 ●  There was significant direct correlation between the Pittsburgh Sleep Quality Index and each of somatization 
subscale of Symptom Checklist-90, depression and anxiety scores in HIV-positive individuals.
Conclusion
 ●  Depression, anxiety and physical morbidity were detected as main factors that affect sleep quality in the HIV-positive 
individuals.
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